Abbott Laboratories Aktie
WKN: 850103 / ISIN: US0028241000
17.07.2025 18:49:33
|
Abbott Reports 10.5% EPS Growth for Fiscal Q2
Abbott Laboratories (NYSE:ABT), a global healthcare company known for its medical devices, diagnostics, nutrition, and pharmaceuticals, reported fiscal 2025 earnings on Thursday, July 17, that narrowly topped analysts' consensus estimates. Q2 revenue climbed to $11.14 billion, surpassing the analyst estimate of $11.06 billion, and adjusted earnings per share came in at $1.26, beating the consensus by $0.01. These results reflect robust year-over-year growth, especially in the company’s Medical Devices segment, which reported year-over-year sales growth of 13.4%, but also highlight continued headwinds in its Diagnostics business, mainly in China. Overall, the company achieved margin expansion and affirmed management’s full-year outlook despite tariff pressures and competitive and regulatory challenges overseas.Source: Abbott Laboratories. Note: Analysts' consensus estimates for the quarter provided by FactSet. YOY = Year over year. bps = basis points.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Q2 Holdings Incmehr Nachrichten
06.05.25 |
Ausblick: Q2 legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net) | |
11.02.25 |
Ausblick: Q2 stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net) |
Analysen zu Abbott Laboratoriesmehr Analysen
Aktien in diesem Artikel
Abbott Laboratories | 106,26 | -0,15% |
|
Abbott Laboratories Cert.Deposito Arg.Repr. 0.5 Shs | 40 150,00 | 0,88% |
|
Q2 Holdings Inc | 75,50 | -1,31% |
|